• About Us
    • About Us
    • Corporate Strategy
    • Our Vision and Values
    • Research & Development
    • Operations
    • Business Development
    • Awards and Grants
  • Announcements
  • Our Team
    • Management Team
    • Scientific Team
    • Scientific Advisory Board
  • Portfolio
    • Our Portfolio
    • Lupuzor™ & Lupus
    • Autoimmunity
    • Metabolism
    • Anti-infectives
    • Cancer
  • Investors
    • Investor Relations
    • AIM Rule 26 Information
    • Euronext Growth
    • Regulatory News
    • Market Commentary
    • Share Price
    • Analyst Research
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Interviews
    • Professional Advisers
    • Email Alerts
  • Media
    • Events and Conferences
    • Media Room
    • Interviews
    • Scientific Publications
  • Contact Us
Archives
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
December 19, 2019

Admission to trading on Euronext Growth Brussels

Read More
December 17, 2019

Publication of Information Note – In advance to admission to trading on Euronext Growth Brussels

Read More
December 13, 2019

Dual listing on Euronext growth Brussels

Read More
December 11, 2019

Share price volatility

Read More
December 03, 2019

ImmuPharma to present at Biotech Showcase™ 2020 in San Francisco

Read More
December 02, 2019

TR1 – Notification of major interest in shareholdings

Read More
November 28, 2019

ImmuPharma and Avion Pharmaceuticals sign exclusive licence

Read More
September 30, 2019

INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2019

Read More
July 04, 2019

TR1 – Notification of Major Interest – Lanstead Capital Investors

Read More
July 02, 2019

TR1 – Notification of Major Shareholding

Read More
June 28, 2019

2019 Annual General Meeting – All resolutions passed

Read More
June 28, 2019

Primary endpoint successfully met from the open label extension study evaluating safety and tolerability from the Pivotal Phase III trial of Lupuzor™ in patients with Systemic Lupus Erythematosus (“Lupus”)

Read More
  • 1
  • 2
Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2021 | All rights reserved

Cookies

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the Cookie Policy